Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (NCT03313778)

🧪 Interventions in This Study

• mRNA-4157 (BIOLOGICAL)
• Pembrolizumab (BIOLOGICAL)
• SoC Treatment (BIOLOGICAL)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (20 Sites)

• Angeles Clinic and Research Institute — Los Angeles, California
• The George Washington Cancer Center — Washington D.C., District of Columbia
• Orlando Health Cancer Institute — Orlando, Florida
• Florida Cancer Specialists — Sarasota, Florida
• H Lee Moffitt Cancer Center and Research Institute — Tampa, Florida
• Massachusetts General Hospital — Boston, Massachusetts
• NYU Langone Medical Center — New York, New York
• The Cleveland Clinic Foundation — Cleveland, Ohio
• UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
• UT Southwest Medical Center — Dallas, Texas
• St Vincents Hospital Sydney — Darlinghurst, New South Wales
• Westmead Hospital-Cnr Hawkesbury and Darcy Road — Westmead, New South Wales
• One Clinical Research Perth — Nedlands, Western Australia
• National Cancer Center East — Kashiwa-Shi, Chiba
• National Cancer Center Hospital — Chuo-Ku, Tokyo
• The Cancer Institute Hospital of Japanese Foundation For Cancer Research — Tokyo,
• Kindai University Hospital — Osakasayama-Shi, Ôsaka
• Ninewells Hospital - PPDS — Dundee, Scotland
• Royal Mardsen Sutton — Sutton, Surrey
• Imperial College Healthcare NHS Trust Hammersmith Hospital — London,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Solid Tumors

• Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors — Basking Ridge, New Jersey
• Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours — Edmonton, Alberta
• Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) — Santa Monica, California
• A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial — Porto Alegre, Rio Grande do Sul
• Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors — Phoenix, Arizona

Explore by condition: All Solid Tumors clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.